Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases

Talawar Therapeutics has agreed to merge with JATT II Acquisition Corp. in a definitive business combination, creating a publicly listed biotechnology company. The deal will see JATT become a subsidiary, with the new entity listing on Nasdaq.

Talawar’s focus is on developing bispecific antibody therapies for inflammatory and immune-mediated (I&I) diseases, including eczema. Coverage highlights the potential market impact of Talawar’s bispecific approach, with *statnews.com* and *Fierce Biotech* framing it as a bid to shake up the eczema treatment landscape. *Endpoints News* notes the Nasdaq listing alongside AstraZeneca’s Phase 3 success in a pediatric bone disease trial, though the latter is unrelated to the merger. *TradingView* and *PR Newswire* confirm the SPAC structure and the deal’s terms.

The merger will accelerate Talawar’s pipeline, particularly its lead asset targeting eczema. Watch for Nasdaq listing details and clinical progress updates, as well as potential investor interest in bispecific therapies for dermatological conditions.